Featured Post

Who Gets Excluded from Psychedelic Trials in GAD, and Why

September 16, 2026

Psychedelic trials in generalized anxiety disorder exclude participants based on cardiac risk from 5-HT2B agonism, personal and family psychiatric history, and psychotropic washout requirements.
 Read More

Other top stories

Measurement-Based Care in Generalized Anxiety Disorder

September 16, 2026

Similar Outcomes With 2-Week and 4-Week Tapers to Xanomeline-Trospium

September 10, 2026

Xanomeline-Trospium and EPS: Low Rates Across Trials, Comparative Data Remain Limited

September 10, 2026

The latest news on Psychopharmacology

Could Psilocybin Help Parkinson’s Patients, Too?

Could Psilocybin Help Parkinson’s Patients, Too?
Administration, Professional Groups Trade Barbs Over Psychotropics

Administration, Professional Groups Trade Barbs Over Psychotropics
RE104 Offers a Revolutionary Approach to Postpartum Depression

RE104 Offers a Revolutionary Approach to Postpartum Depression
Weekly Mind Reader: Clinicians Tackle Psychedelics

Weekly Mind Reader: Clinicians Tackle Psychedelics

Other stories

Improved but Not Recovered: The Relapsing Course of Generalized Anxiety Disorder

August 28, 2026

Safety Across Classic Psychedelics in GAD: What Three Investigational Programs Show So Far

August 28, 2026

The Weakened Brake: Circuit and Synaptic Biology in Generalized Anxiety Disorder

August 1, 2026

The Receptor at the Center of Psychedelic Therapies for GAD

August 1, 2026

2026 Congress Coverage: The Persistence Problem in GAD and Treatment-Resistant Depression

July 27, 2026

Psychedelics Are Advancing in GAD, but None Are Yet Approved

July 16, 2026

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe